Private Equity

The acquisition of Pathway Capital creates a $185B giant, signaling a new phase of consolidation where scale is king and private markets open to new money.

With a novel 'gastric bypass in a pill' and a new CFO known for orchestrating lucrative exits, Syntis Bio is gearing up for a high-stakes battle in the booming obesity drug market.

New research reveals Indigenous-led projects are not just a social good, but a critical economic engine for Canada's energy transition and resource economy.

New data on elecoglipron, an oral pill with no food restrictions, shows major weight loss and A1C reduction, positioning AstraZeneca to disrupt the GLP-1 market.

Millions of Americans face a hidden tax threat within their retirement accounts. A new book by financial professionals details the risks and offers strategies.

As Vivos Therapeutics pitches its revolutionary sleep apnea solution to investors, it's not just selling a device; it's fighting for its financial life.

With a complex $72M financing deal, Park Systems is doubling down on its dominance in nanometrology. Is this the move that makes them indispensable to chip giants?

Leilani Farha’s Massey Lectures put the financialization of housing on trial, exposing a system where homes are assets and displacement is profit.

Cadogan Tate's acquisition of a Phoenix specialist isn't just a deal; it's a masterclass in building a global network for the ultra-wealthy.

The firm's high-level hires from rival firms signal a calculated move to dominate the lucrative credit and opportunistic investment landscape amid market shifts.

With a new $4.3B war chest, Hunter Point Capital is evolving from a GP stakes firm into a scaled solutions platform, meeting a critical need for liquidity.

After years of stabilization, a 90% stake in real estate firm DEMIRE is for sale. The move by Apollo and Wecken & Cie. could reshape the firm and signal a market shift.

With expanded coverage for 52 million Americans, Tonix Pharmaceuticals' TONMYA® is not just a drug launch; it's a market disruption for chronic pain.

Ares Capital, a giant in middle-market finance, just opened a new $1B funding spigot. Is this a blueprint for the BDC industry or a sign of cheaper capital for American businesses?

EQT appoints M&A mastermind Gustav Segerberg as CFO, signaling a doubling-down on its aggressive growth strategy. What does this mean for its future?

A Toronto meeting signals a new era for Canada-Grenada ties. It's a calculated move into geothermal energy, regional security, and high-value trade.

A new study on hedge fund titans reveals a startling truth: in the age of AI, a dense narrative of books and ideas matters more than assets under management.

Blink Charging is selling its Envoy subsidiary to focus on core infrastructure. This isn't just a deal; it's a sign that the EV industry's era of frantic growth is giving way to a new mandate: profitability.

As Royalty Pharma prepares for a key investor conference, we explore the powerful, low-profile business model that funds blockbuster drugs and shapes innovation.

HELP USA's recent gala honored leaders in housing, but the real story is the innovative fusion of finance, policy, and healthcare creating scalable solutions.